Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature.
Anti-tumor necrosis factor-alpha (TNF-alpha) immunotherapy is revolutionizing the treatment of immune disease, particularly Crohn's disease, rheumatoid arthritis, psoriatic arthritis and psoriasis. The role of anti-TNF-alpha agents in the management of cutaneous lupus erythematosus (LE), however, is not as clear. While experimental reports have suggested a potential benefit of anti-TNF-alpha therapy in severe cutaneous LE, newer reports have identified these medications as instigators or exacerbators of the disease. In this review, the authors present a case of a patient whose persistent discoid LE (DLE) was exacerbated by a trial of adalimumab, one of the currently available TNF-alpha-blocking agents. The authors review 128 cases in the literature in which anti-TNF-alpha therapy was implicated in cutaneous LE pathogenesis, with emphasis on DLE, and consider a number of mechanisms whereby this arguably paradoxical effect may occur. The authors then propose possible approaches to the management of anti-TNF-alpha therapy-induced cutaneous LE.